The 3TR PRECIS-THE-RA trial will directly test whether assigning RA patients to either a TNF-inhibitor or an IL6-inhibitor based on the probability of response determined through a synovial biopsy nCounter assay will enrich for clinical response compared to the control arm, in which patients will receive one of the two drugs randomly. The gene discussed is TNF; the disease is rheumatoid arthritis.